Molindone

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Molindone
Molindone.svg
Systematic (IUPAC) name
3-ethyl-2-methyl-5-(morpholin-4-ylmethyl)-
1,5,6,7-tetrahydro-4H-indol-4-one
Clinical data
Trade names Moban
AHFS/Drugs.com Consumer Drug Information
MedlinePlus a682238
Pregnancy cat. C
Legal status Prescription only
Routes Oral
Pharmacokinetic data
Metabolism Hepatic
Half-life 1.5 hours
Excretion Minor, renal and fecal
Identifiers
CAS number 7416-34-4 YesY
ATC code N05AE02
PubChem CID 23897
IUPHAR ligand 207
DrugBank DB01618
ChemSpider 22342 YesY
UNII RT3Y3QMF8N YesY
KEGG D08226 YesY
ChEMBL CHEMBL460 YesY
Chemical data
Formula C16H24N2O2 
Mol. mass 276.374 g/mol
 N (what is this?)  (verify)

Molindone (Moban) is a therapeutic antipsychotic, used in the treatment of schizophrenia.[1] It works by blocking the effects of dopamine in the brain, leading to diminished psychoses. It is rapidly absorbed when taken by mouth.

It is sometimes described as a typical antipsychotic,[2] and sometimes described as an atypical antipsychotic.[3]

Molindone was discontinued by its sole supplier, Endo Pharmaceuticals, on January 13, 2010. [4]

Adverse effects[edit]

Main article: Typical antipsychotic

The side effect profile of molindone is similar to that of other typical antipsychotics. Unlike most antipsychotics, however, molindone use is associated with weight loss.[3][5]

See also[edit]

References[edit]

  1. ^ "molindone". F.A. Davis Company. 
  2. ^ Aparasu RR, Jano E, Johnson ML, Chen H (October 2008). "Hospitalization risk associated with typical and atypical antipsychotic use in community-dwelling elderly patients". Am J Geriatr Pharmacother 6 (4): 198–204. doi:10.1016/j.amjopharm.2008.10.003. PMID 19028375. 
  3. ^ a b Bagnall A, Fenton M, Kleijnen J, Lewis R (2007). "Molindone for schizophrenia and severe mental illness". In Bagnall, Anne-Marie. Cochrane Database Syst Rev (1): CD002083. doi:10.1002/14651858.CD002083.pub2. PMID 17253473. 
  4. ^ http://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm050794.htm
  5. ^ Allison DB, Mentore JL, Heo M et al. (1999). "Antipsychotic-induced weight gain: a comprehensive research synthesis". Am J Psychiatry 156 (11): 1686–96. PMID 10553730.  Free full text